ClinicalTrials.gg
TerminatedNCT00644878MACS0254Updated Aug 18, 2021Results posted

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

A Phase 2 interventional study of Nilotinib in Chronic Myelogenous Leukemia - Chronic Phase, sponsored by Novartis Pharmaceuticals. Terminated at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-18.

Primary conditionLeukemia, Myelogenous, Chronic, BCR-ABL PositiveRegistry: Leukemia, Myeloid, Chronic-PhaseReclassifiedWhy we changed it
Registry
Leukemia, Myeloid, Chronic-Phase — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Why
  1. Leukemia, Myeloid, Chronic-Phase is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
Slower than expected enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
51st of 66
18 · median 55
Started
2008
with 4 others
Phase 2
25 of 66
1 open now
Registered
9th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 51st largest by enrollment, is one of 5 that started in 2008, is one of 25 in phase 2, and was the 9th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

This exploratory study will evaluate the change in molecular response in chronic myelogenous leukemia - chronic phase patients with a complete cytogenetic response and have a suboptimal molecular response to imatinib

03

Conditions studied

  • Chronic Myelogenous Leukemia - Chronic Phase

Keywords

  • leukemia
  • chronic myelogenous leukemia
  • chronic phase
  • molecular response
  • nilotinib
  • ENABL
04

In context

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Reclassified

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

This study's enrollment of 18 is below the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia, Myeloid, Chronic-Phase. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Select Inclusion Criteria:

  • Male or female patients ≥ 18 years of age with a confirmed diagnosis of Ph+ CML-CP and CCyR
  • A suboptimal molecular response to imatinib defined as:

    • Group 1: Treated with 1 year of imatinib, complete cytogenetic response (CCyR) but no major molecular response (MMR) (Bcr-Abl levels >0.1%IS);
    • Group 2: No specific duration of imatinib required, achieved CCyR but has >1 log increase in Bcr-Abl transcript levels
  • Adequate end organ function
  • Patients must have had an imatinib of at least 3 days and not to exceed 7 days prior to the first dose of nilotinib. Group 1 patients must have been treated with imatinib for at least 1 year. There was no imatinib treatment duration requirement for Group 2 patients.
  • For Group 1, patients were eligible for screening if they were treated with an imatinib dose of at least 400mg daily. Dose reduction could have occurred as long as the minimum dose was 300mg daily and the reduction lasted ≤ 28 days. The patient was required to be on 400 mg daily (or a higher dose) of imatinib for at least 6 consecutive months leading up to screening for this study.
  • For Group 2 patients, dose reduction while on imatinib could have occurred as long as the minimum dose was 300 mg daily, and the reduction lasted ≤28 days.

Select Exclusion Criteria:

  • Prior accelerated phase or blast crisis CML
  • Patients achieving prior CCyR on imatinib who lost cytogenetic response prior to entering study
  • Previously documented T315I mutations
  • Prior therapy with any other tyrosine kinase inhibitor except imatinib
  • Patients with to receiving nilotinib, including concomitant medications
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Nilotinib

    Drug: Nilotinib

Interventions

  • Nilotinib 300 mg is taken by mouth twice a day at 12 hour intervals. Nilotinib is to be taken with water on an empty stomach. No food two hours prior to the dose of nilotinib and for one hour following the dose.

    Also known as: Tasigna, AMN 107

07

What researchers measure

Primary outcomes

  1. Log Change From Baseline in Breakpoint Cluster Region Gene (BCR) - Abelson Proto-oncogene (ABL) (Bcr-Abl) Transcript Levels

    The change on a logarithmic scale at 12 months from a standardized baseline value (100% on the international scale \[IS\]) in Bcr-Abl transcripts as assessed by peripheral blood Quantitative real-time polymerase chain reaction (RQ-PCR).

    Time frame: From Baseline up to 12 Months

Secondary outcomes

  1. Number of Participants Who Achieved Major Molecular Response (MMR)

    Major Molecular Response (MMR) value at molecular MD is designated a percentage, which is equivalent to a 3-log reduction from a standardized baseline value from the International Randomized InteYesrferon versus STI571 (IRIS) study or 0.1 percent (%) per International Scale (IS).

    Time frame: From Baseline up to 12 Months

  2. Number of Participants Achieved Reduction From a Standardized Baseline Value in Bcr-Abl Transcript Levels up to Month 12

    Number of participants experiencing either a greater than or equal to (\>or=) 1, \>or= 2, or \>or= 3 log10 reduction in Bcr-Abl transcript levels from Baseline to End of Cycle (EOC) 45 (Day1219 - Day1302) were presented.

    Time frame: From Baseline up to 12 Months

  3. Median Time to Best Molecular Response

    The median time to best molecular response, defined as the time (in months) from the date of enrollment to the date when the maximum reduction in Bcr-Abl transcript level was observed.

    Time frame: From Start of Study up to End of the Study (up to 41 Months)

  4. Duration of Best Molecular Response

    Duration of best molecular response, defined as the time (in months) from the date of best molecular response to a date when an increase in \>1 log10 was observed

    Time frame: From Start of Study up to End of the Study (up to 41 Months)

  5. Number of Participants With an Event-free Survival

    Event-free survival was defined as the number of participants from the date of enrollment to the date of first occurrence of any of the following: loss of complete hematological response (CHR), loss of Complete cytogenetic response (CCyR), \>1 log increase in Bcr-Abl transcripts from the lowest recorded value, progression to accelerated or blast phase, and death.

    Time frame: From Start of Study up to End of the Study (up to 41 Months)

  6. Number of Participants With a Progression-free Survival

    Progression-free survival was defined as the number of participants from the date of enrollment to the date of first occurrence of progression to Accelerated phase (AP) or Blast crisis (BC) phase, chronic myelogenous leukemia (CML) or death. Participants who did not have an event or dropped out without an event are considered censored at the date of the last observed event.

    Time frame: From Start of Study up to End of the Study (up to 41 Months)

  7. Number of Participants With an Overall Survival

    Overall survival was defined as the number of participants from enrollment to the date of death.

    Time frame: From Start of Study Enrollment up to End of the Study (up to 41 Months)

08

Results

Posted Aug 18, 2021
Limitations and caveats
The study was terminated on 31 March 2012 due to slower than planned enrollment, resulting in a small sample size, no inferential analyses were conducted.

Participant flow

The study was conducted at 12 centers in United States.

Participant flow — Overall Study
MilestoneNilotinib
Started18
Completed0
Not completed18
Withdrew: Adverse event2
Withdrew: Abnormal laboratory value3
Withdrew: Protocol deviation2
Withdrew: Treatment duration completed as per protocol11

Outcome measures

PrimaryLog Change From Baseline in Breakpoint Cluster Region Gene (BCR) - Abelson Proto-oncogene (ABL) (Bcr-Abl) Transcript Levels

The change on a logarithmic scale at 12 months from a standardized baseline value (100% on the international scale \[IS\]) in Bcr-Abl transcripts as assessed by peripheral blood Quantitative real-time polymerase chain reaction (RQ-PCR).

Time frame:
From Baseline up to 12 Months
Reported as:
Mean · log change
Log Change From Baseline in Breakpoint Cluster Region Gene (BCR) - Abelson Proto-oncogene (ABL) (Bcr-Abl) Transcript Levels
log changeNilotinib
Baseline2.229 ± 0.6165
Month 123.612 ± 0.5689
SecondaryNumber of Participants Who Achieved Major Molecular Response (MMR)

Major Molecular Response (MMR) value at molecular MD is designated a percentage, which is equivalent to a 3-log reduction from a standardized baseline value from the International Randomized InteYesrferon versus STI571 (IRIS) study or 0.1 percent (%) per International Scale (IS).

Time frame:
From Baseline up to 12 Months
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Major Molecular Response (MMR)
ParticipantsNilotinib
Baseline — Response: Yes0
Baseline — Response: No18
Baseline — Response: Missing0
Month 12 — Response: Yes9
Month 12 — Response: No3
Month 12 — Response: Missing6
SecondaryNumber of Participants Achieved Reduction From a Standardized Baseline Value in Bcr-Abl Transcript Levels up to Month 12

Number of participants experiencing either a greater than or equal to (\>or=) 1, \>or= 2, or \>or= 3 log10 reduction in Bcr-Abl transcript levels from Baseline to End of Cycle (EOC) 45 (Day1219 - Day1302) were presented.

Time frame:
From Baseline up to 12 Months
Reported as:
Count of participants · Participants
Number of Participants Achieved Reduction From a Standardized Baseline Value in Bcr-Abl Transcript Levels up to Month 12
ParticipantsNilotinib
>or=1 log10 reduction12
>or= 2 log10 reduction12
>or= 3 log109
SecondaryMedian Time to Best Molecular Response

The median time to best molecular response, defined as the time (in months) from the date of enrollment to the date when the maximum reduction in Bcr-Abl transcript level was observed.

Time frame:
From Start of Study up to End of the Study (up to 41 Months)
Reported as:
Median · months
Median Time to Best Molecular Response
monthsNilotinib
Median Time to Best Molecular Response13.8 (4.2 to 23.1)
SecondaryDuration of Best Molecular Response

Duration of best molecular response, defined as the time (in months) from the date of best molecular response to a date when an increase in \>1 log10 was observed

Time frame:
From Start of Study up to End of the Study (up to 41 Months)

No measurements were reported for this outcome.

SecondaryNumber of Participants With an Event-free Survival

Event-free survival was defined as the number of participants from the date of enrollment to the date of first occurrence of any of the following: loss of complete hematological response (CHR), loss of Complete cytogenetic response (CCyR), \>1 log increase in Bcr-Abl transcripts from the lowest recorded value, progression to accelerated or blast phase, and death.

Time frame:
From Start of Study up to End of the Study (up to 41 Months)
Reported as:
Count of participants · Participants
Number of Participants With an Event-free Survival
ParticipantsNilotinib
Event1
Censor17
SecondaryNumber of Participants With a Progression-free Survival

Progression-free survival was defined as the number of participants from the date of enrollment to the date of first occurrence of progression to Accelerated phase (AP) or Blast crisis (BC) phase, chronic myelogenous leukemia (CML) or death. Participants who did not have an event or dropped out without an event are considered censored at the date of the last observed event.

Time frame:
From Start of Study up to End of the Study (up to 41 Months)
Reported as:
Count of participants · Participants
Number of Participants With a Progression-free Survival
ParticipantsNilotinib
Censor15
Missing3
SecondaryNumber of Participants With an Overall Survival

Overall survival was defined as the number of participants from enrollment to the date of death.

Time frame:
From Start of Study Enrollment up to End of the Study (up to 41 Months)
Reported as:
Count of participants · Participants
Number of Participants With an Overall Survival
ParticipantsNilotinib
Number of Participants With an Overall Survival18

Adverse events

Collected over From Start of Study to End of the Study (up to 41 Months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib0/18 (0%)3/18 (16.7%)18/18 (100%)
Most frequent serious events
Most frequent serious events
EventNilotinib
BradycardiaCardiac disorders1/18
VertigoEar and labyrinth disorders1/18
PancreatitisGastrointestinal disorders1/18
PneumoniaInfections and infestations1/18
SinusitisInfections and infestations1/18
Most frequent other events
Showing 10 of 108
Most frequent other events
EventNilotinib
FatigueGeneral disorders6/18
ArthralgiaMusculoskeletal and connective tissue disorders5/18
HeadacheNervous system disorders5/18
RashSkin and subcutaneous tissue disorders5/18
NauseaGastrointestinal disorders4/18
SinusitisInfections and infestations4/18
Upper respiratory tract infectionInfections and infestations4/18
MyalgiaMusculoskeletal and connective tissue disorders4/18
CoughRespiratory, thoracic and mediastinal disorders4/18
Dry eyeEye disorders3/18

Baseline characteristics

The analysis was performed in Intent-to-treat (ITT) population, defined as all enrolled participants who received at least 1 dose of study drug and had at least 1 post-baseline assessment.

Age, Continuous
Age, Continuous(years)Nilotinib
Mean45.7 ± 12.15
Sex: Female, Male
Sex: Female, Male(Participants)Nilotinib
Female7
Male11
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nilotinib
Caucasian14
Black0
Asian1
Other3
09

Study locations

11 sites
  • USC Norris Cancer Center Jane Anne Nohl
    Los Angeles, California 90033, United States
  • Georgia Health Sciences University Dept. of MCG
    Augusta, Georgia 30912, United States
  • Indiana Blood and Marrow Institute
    Beech Grove, Indiana 46107, United States
  • University of Iowa Hospitals & Clinics Univ of Iowa Hosp & Clinic
    Iowa City, Iowa 52242, United States
  • LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center
    New Orleans, Louisiana 70115, United States
  • St. Agnes Hospital
    Baltimore, Maryland 21229, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 29615, United States
  • South Texas Institute of Cancer
    Corpus Christi, Texas 78405, United States
  • Baylor College of Medicine - Breast Care Dan L Duncan Cancer Ctr
    Houston, Texas 77030, United States
  • Central Utah Clinic Central Utah Clinic (7)
    Provo, Utah 84604, United States
  • Froedert Memorial Lutheran Hospital Dept.ofFroedert Memorial
    Milwaukee, Wisconsin 53226, United States
10

References and documents

Publications

  • Ailawadhi S, Akard LP, Miller CB, Jillella A, DeAngelo DJ, Ericson SG, Lin F, Warsi G, Radich J. Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib. Ther Adv Hematol. 2017 Jan;8(1):3-12. doi: 10.1177/2040620716678118. Epub 2016 Nov 24. PubMed 28042454 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2021, 9 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2008
First posted
Mar 27, 2008
Start
Oct 2008
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Results first posted
Aug 18, 2021
Last update
Aug 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00644878
Responsible party
Sponsor
First posted
Mar 27, 2008
Start date
Oct 2008
Primary completion
Mar 2012
Completion
Mar 2012
Results posted
Aug 18, 2021
Last update
Aug 18, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion